modelPiperazine
Extends from Pharmacolibrary.Drugs.ATC.P.P02CB01.
Information
| name: | Piperazine | |
| ATC code: | P02CB01 | route: | oral |
| compartments: | 1 | |
| dosage: | 4000 | mg |
| volume of distribution: | 0.23 | L |
| clearance: | 1.5 | L/h |
| other parameters in model implementation | ||
Piperazine is an anthelmintic drug historically used for the treatment of intestinal nematode infections, primarily ascariasis and enterobiasis (pinworm). It paralyzes helminths by acting as a GABA agonist at the neuromuscular junction, making them more easily removed from the host's intestines. Its use has decreased with the introduction of more effective drugs, but it is still available in some regions for these indications.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects following oral administration.
References
Davis, JL, et al., & Medlin, E (2018). Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse. Journal of veterinary pharmacology and therapeutics 41(3) 393–401. DOI:10.1111/jvp.12477 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29333613
Steiger, H, et al., & Young, SN (2003). Implications of compulsive and impulsive traits for serotonin status in women with bulimia nervosa. Psychiatry research 120(3) 219–229. DOI:10.1016/s0165-1781(03)00195-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14561433
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)